Fig. 3
From: Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
CD8+ T-cell depletion in EMT6 tumor-primed mice triggers the growth of DTCs. EMT6-Luc tumor-bearing mice at 4 weeks post implantation were treated with two doses of anti-CD8α antibody (500 μg/mouse); first dose 1 day before the resection of primary tumors and the second dose was administered 2 days after the resection. ***P < 0.0005, two-way analysis of variance test. a–c Depletion of CD8+ T cells enhanced the outgrowth of spontaneously disseminated tumor cells, when compared with isotype-treated mice, which showed no metastasis after the resection of primary tumors. EMT6-primed mice were treated with two doses of a CD8β antibody (500 μg/mouse); one dose 1 day before the tail vein injection of EMT6-Luc cells and the second dose 2 days after was administered. d, e CD8+ T cells were efficiently depleted in antibody-treated mice compared with the isotype control-treated animals. ***P < 0.0005, two-tailed Student’s t test. f, g Depletion of CD8+ T cells promoted the outgrowth of tail vein-injected EMT6-Luc cells, while isotype-treated mice effectively eliminated these cells. Results are presented as mean ± SD (n = 5 for each group). ***P < 0.0005, two-way analysis of variance test
